|Articles|January 27, 2023
Scaling Up Antibody-Drug Conjugate Payloads
Author(s)Lonza
Newer, more complex targeted therapies are entering clinical development at rapid speeds, requiring facilities to increase manufacturing capacity levels in order to keep up with demands and under the strictest levels of containment.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
2
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
3
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
4
De-risking Biologic Development: Engineering Flexibility from Early Development to Launch
5